VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Aug. 28, 2006) - Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, today announced it has begun dosing in a Phase Ib human clinical trial evaluating the Company's product AL-108 as a treatment for Alzheimer's disease.
